Cic edizioni internazionali
Functional Neurology

Effect of zolpidem in chronic disorders of consciousness: a prospective open-label study

Original Article, 259 - 264
doi: 10.11138/FNeur/2013.28.4.259
Tag this article
Abstract
Enhanced HTML Full text PDF
Zolpidem has been reported as an “awakening drug” in some patients with disorders of consciousness (DOC).
We here present the results of a prospective openlabel study in chronic DOC patients. Sixty patients (35±15 years; 18 females; mean time since insult ± SD: 4±5.5 years; 31 with traumatic etiology) with a diagnosis of vegetative state/unresponsive wakefulness syndrome (n=28) or minimally conscious state (n=32) were behaviorally assessed using the Coma Recovery Scale-Revised (CRS-R) before and one hour after administration of 10 mg of zolpidem. At the group level, the diagnosis did not change after intake of zolpidem (p=0.10) and CRS-R total scores decreased (p=0.01). Twelve patients (20%) showed improved behaviors and/or CRS-R total scores after zolpidem administration but in only one patient was the diagnosis after zolpidem intake found to show a significant improvement (functional object use), which suggested a change of diagnosis. However, in this patient, a double-blind placebo-controlled trial was performed in order to better specify the effects of zolpidem, but the patient, on this trial, failed to show any clinical improvements.
The present open-label study therefore failed to show any clinically significant improvement (i.e., change of Effect of zolpidem in chronic disorders of consciousness: a prospective open-label study diagnosis) in any of the 60 studied chronic DOC patients

Vol. XXXII (No. 2) 2017 April/June

  1. The past and future of Functional Neurology
    D'Angelo E., Boller F., Wheeler-Kingshott C.G., Vanacore N., Sandrini G., Cisari C., Tamburin S., Baricich A.
    doi: 10.11138/FNeur/2017.32.2.061
  2. European core curriculum in neurorehabilitation
    Sandrini G., Binder H., Hömberg V., Saltuari L., Tarkka I., Smania N., Corradini C., Giustini A., Kätterer C., Picari L., Diserens K., Koenig E., Geurts A., Anghelescu A., Opara J., Tonin P., Kwakkel G., Golyk V., Onose G., Pérennou D., Picelli A.
    doi: 10.11138/FNeur/2017.32.2.063
  3. Object decision and multiple sclerosis: a preliminary study
    Caputi N., Matrella A., Totaro R., Raparelli C., Pontecorvo S., Di Giacomo D., Passafiume D.
    doi: 10.11138/FNeur/2017.32.2.069
  4. Cerebellar transcranial static magnetic field stimulation transiently reduces cerebellar brain inhibition
    Matsugi A., Okada Y.
    doi: 10.11138/FNeur/2017.32.2.077
  5. HLA-DRB1*15 association with multiple sclerosis is confirmed in a multigenerational Italian family
    Mosca L., Mantero V., Penco S., La Mantia L., De Benedetti S., MArazzi M.R., Spreafico C., Erminio C., Grassi L., Lando G., Zagaria M., Agostoni E., Protti A.
    doi: 10.11138/FNeur/2017.32.2.083
  6. The Italian real-life post-stroke spasticity survey: unmet needs in the management of spasticity with botulinum toxin type A
    Picelli A., Baricich A., Cisari C., Paolucci S., Smania N., Sandrini G.
    doi: 10.11138/FNeur/2017.32.2.089
  7. Sensitivity of multi-shell NODDI to multiple sclerosis white matter changes: a pilot study
    Schneider T., Brownlee W., Zhang H., Ciccarelli O., Miller D.H., Wheeler-Kingshott C.G.
    doi: 10.11138/FNeur/2017.32.2.097
  8. Ixcellence Network®: an international educational network to improve current practice in the management of cervical dystonia or spastic paresis by botulinum toxin injection
    Fheodoroff K., Bhidayasiri R., Jacinto L.J., Chung T.M., Bhatia K., Landreau T., Colosimo C.
    doi: 10.11138/FNeur/2017.32.2.103
Last Viewed articles: la lista degli ultimi x visitati.
  1. Effect of zolpidem in chronic disorders of consciousness: a prospective open-label study
    Thonnard M., Gosseries O., Demertzi A., Lugo Z., Vanhaudenhuyse A., Bruno M.A., Chatelle C., Thibaut A., Charland-Verville V., Habbal D., Schnakers C., Laureys S.
    doi: 10.11138/FNeur/2013.28.4.259
credits